Success Metrics

Active Trials

3(75%)

Phase Distribution

Ph phase_2

25%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Active, not recruiting2

Not yet recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

not_yet_recruiting125%

active_not_recruiting250%

recruiting125%

Recent Activity

3 active trials

Showing 4 of 4

active_not_recruitingphase_1

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

NCT05882734

active_not_recruitingphase_1

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

NCT04170153

recruitingphase_2

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

NCT06518564

not_yet_recruitingphase_1

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

NCT05986071

Clinical Trials (4)

Showing 4 of 4 trials

NCT05882734Phase 1

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active Not Recruiting

NCT04170153Phase 1

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active Not Recruiting

NCT06518564Phase 2

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Recruiting

NCT05986071Phase 1

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

Not Yet Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4